CTRI/2019/03/018340尚未招募未知
To Study the Efficacy of Ferrum Phos 6x in the Homoeopathic Management of Iron Deficiency Anaemia in Adolescent School Girls.
Dr Indrajeet P Shah0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age group 10â??19 years.
- •2.adolescent school girls suffering from mild to moderate Anaemia with Haemoglobin ranging between 7-12 g/dL
- •3.Subjects diagnosed on the basis of clinical presentation, laboratory investigation like Hb gm % & peripheral smear.
- •4.Patients from all communities, female sex, different socio-economic status is included.
排除标准
- •1.Anaemia with established and advanced pathological changes i.e. Leukaemia, Multiple myeloma, sickle cell Anaemia, Thalassemia.
- •2.Patients requiring hospitalization due to surgical intervention or due to other diseases with anaemia.
- •3.Underlying chronic illness like immunocompromised, Pulmonary Tuberculosis.
研究者
相似试验
尚未招募
2 期
Ferrum phosphoricum in AnaemiaCTRI/2024/02/062641Central Council for Research in Homoeopathy
招募中
2 期
A single-centre feasibility study to evaluate the ability of Phoxilium to prevent hypophoshatemia compared to Hemosol B0 or Prismocol B22 during continuous renal replacement therapy in the intensive care unitRenal and Urogenital - Other renal and urogenital disordersAcute kidney injuryACTRN12623001152617Austin Health30
已完成
3 期
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing HemodialysisEnd Stage Renal DiseaseESRDHyperphosphatemiaNCT04456803Sinomune Pharmaceutical Co., Ltd239
进行中（未招募）
1 期
The Effect of Phosphate Lowering in blood using medication called sucroferric oxyhydroxide (PA21) on Calcification Propensity of the blood– a clinical Trial in which people taking part are put into one or other group at random, the treatment is compared to a control treatment , open-label, cross-over trialEUCTR2016-004789-24-ATOrdensklinikum Linz, Krankenhaus der Elisabethinen Linz GmbH, III. Interne
已完成
Unknown
The effect of novel iron-containing phosphate binder,ferric citrate, to serum P,Ca,and iron metabolic markers on HD patients.HD PatientsJPRN-jRCT1090220207Shigeru Miyazaki20